Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
- PMID: 17330101
- DOI: 10.1038/sj.leu.2404609
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
Abstract
The leukemic stem cells in patients with chronic myeloid leukemia (CML) are well known to be clinically resistant to conventional chemotherapy and may also be relatively resistant to BCR-ABL-targeted drugs. Here we show that the lesser effect of imatinib mesylate (IM) on the 3-week output of cells produced in vitro from lin(-)CD34(+)CD38(-) CML (stem) cells compared with cultures initiated with the CD38(+) subset of lin(-)CD34(+) cells is markedly enhanced (>10-fold) when conditions of reduced growth factor stimulation are used. Quantitative analysis of genes expressed in these different CML subsets revealed a differentiation-associated decrease in IL-3 and G-CSF transcripts, a much more profound decrease in expression of BCR-ABL than predicted by changes in BCR expression, decreasing expression of ABCB1/MDR and ABCG2 and increasing expression of OCT1. p210(BCR-ABL) and kinase activity were also higher in the lin(-)CD34(+)CD38(-) cells and formal evidence that increasing BCR-ABL expression decreases IM sensitivity was obtained from experiments with a cell line model. Nevertheless, within the entire CD34(+) subset of CML cells, BCR-ABL expression was not strongly affected by changes in cell cycle status. Taken together, these results provide the first evidence of multiple mechanisms of innate IM resistance in primitive and quiescent CML cells.
Similar articles
-
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.Cancer Res. 2005 Oct 1;65(19):8912-9. doi: 10.1158/0008-5472.CAN-05-0076. Cancer Res. 2005. PMID: 16204063
-
Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.Leukemia. 2008 Mar;22(3):559-71. doi: 10.1038/sj.leu.2405057. Epub 2007 Dec 6. Leukemia. 2008. PMID: 18059481
-
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27. J Natl Cancer Inst. 2013. PMID: 23446755 Free PMC article.
-
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. doi: 10.1016/j.critrevonc.2005.06.007. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16213151 Review.
-
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.Br J Haematol. 2008 Jul;142(3):361-78. doi: 10.1111/j.1365-2141.2008.07197.x. Epub 2008 Jun 5. Br J Haematol. 2008. PMID: 18540942 Review.
Cited by
-
miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1.Am J Transl Res. 2016 Feb 15;8(2):447-59. eCollection 2016. Am J Transl Res. 2016. PMID: 27158338 Free PMC article.
-
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.Blood. 2010 Sep 23;116(12):2112-21. doi: 10.1182/blood-2009-05-222471. Epub 2010 Jun 23. Blood. 2010. PMID: 20574046 Free PMC article.
-
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.Genes Cancer. 2010 Jan;1(1):40-9. doi: 10.1177/1947601909358324. Genes Cancer. 2010. PMID: 20811583 Free PMC article.
-
BCR-ABL kinase is dead; long live the CML stem cell.J Clin Invest. 2011 Jan;121(1):22-5. doi: 10.1172/JCI43605. Epub 2010 Dec 13. J Clin Invest. 2011. PMID: 21157035 Free PMC article.
-
An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.Cancers (Basel). 2024 Oct 26;16(21):3615. doi: 10.3390/cancers16213615. Cancers (Basel). 2024. PMID: 39518058 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous